876147-75-0

Usage

Molecular weight

420.92 g/mol The mass of a single molecule of Tazobactam, measured in grams per mole.

Appearance

White or off-white crystalline solid The physical appearance of Tazobactam, which is a white or off-white crystalline solid.

Solubility

Slightly soluble in water, freely soluble in methanol and acetonitrile The solubility of Tazobactam in different solvents, which indicates how well it dissolves in them.

Mechanism of action

Inhibitor of bacterial beta-lactamase enzymes The way Tazobactam works to increase the effectiveness of beta-lactam antibiotics by inhibiting bacterial beta-lactamase enzymes.

Stereochemistry

3S The stereochemistry of Tazobactam, indicating that it is the (S)-enantiomer, which is more biologically active than the (R)-enantiomer.

Use

Combination with beta-lactam antibiotics for enhanced effectiveness against resistant bacteria The primary use of Tazobactam in combination with other antibiotics to increase their effectiveness against antibiotic-resistant bacteria.

Upstream product

• 625471-18-3 tert-butyl (3S)-3-aminopiperidine-1-carboxylate 
• 54001-17-1 2-(4-chlorophenyl)-4-methyl-1,3-thiazole-5-carboxylic acid 

Downstream Products

• 876147-76-1 (S)-N-(piperidin-3-yl)-2-(4-chlorophenyl)-4-methylthiazol-5-ylcarboxamide 

Relevant academic research and scientific papers

Discovery of cyclic amine-substituted benzoic acids as PPARα agonists

A series of novel cyclic amine-substituted benzoic acid derivatives were synthesized and evaluated for their PPARα agonist activity. Strucure-activity relationship studies led to the identification of (S)-3-[3-[2-(4-chlorophenyl)-4-methylthyazole-5-carboxamido]piperidin-1-yl] benzoic acid (S)-4f (KRP-105) as a potent and high subtype-selective human PPARα agonist. (S)-4f showed excellent PK profile and oral administration of (S)-4f to high-fat diet dogs effectively lowered triglycerides.

NOVEL CYCLIC AMINOBENZOIC ACID DERIVATIVE

The present invention relates to cyclic amino benzoic acid derivatives which are effective in therapy of lipid metabolism abnormality, diabetes and the like as a human peroxisome proliferators-activated receptor (PPAR) agonist, in particular, as an agonist against human PPARα isoform, and addition salts thereof, and pharmaceutical compositions containing these compounds. A cyclic amino benzoic acid derivative represented by the general formula (1) [wherein a ring Ar represents an aryl group which may have substituent, or the like; Y represents a C1-C4 alkylene, C2-C4 alkenylene, C2-C4 alkynylene, or the like; Z represents an oxygen atom, sulfur atom or - (CH2)n- (n represents 0,1 or 2) ; X represents a hydrogen atom, halogen atom, lower alkyl group which may be substituted with a halogen atom, or the like; R represents a hydrogen atom or lower alkyl group, and -COOR substitutes for an ortho position or metha position of binding position of ring W] or a pharmaceutically acceptable salt thereof.